Connect with us

Technology

21st.BIO obtains self-affirmed GRAS status for its precision fermented beta-lactoglobulin: 21st.BIO customers can now enter the U.S. market with their own production using 21st.BIO technology

Published

on

21st.BIO has earned a self-affirmed GRAS status for its animal-free beta-lactoglobulin ingredient, which customers can now launch in the United States market.21st.BIO is helping customers bring products to market at an unprecedented pace, from initiation of development to market approval in under two years.21st.BIO offers the leading production technology for BLG, based on precision fermentation technology that has been perfected over decades and partly licensed from Novonesis (formerly Novozymes).By studying the variation in cows’ milk protein, 21st.BIO’s world class scientists have been able to reproduce a highly nutritious recombinant BLG, which is the most potent bovine whey protein and has superior nutrition and functionalities. This is why 21st.BIO has named its protein BLG Essential+™.

COPENHAGEN, Denmark and DAVIS, Calif., Sept. 4, 2024 /PRNewswire/ — Precision fermentation platform provider 21st.BIO has earned a self-affirmed GRAS status for its animal-free beta-lactoglobulin ingredient, BLG Essential+™, which means customers can now launch in the United States market.

This breakthrough comes less than two years after 21st.BIO initiated its development of a strain and production process for its beta-lactoglobulin protein, BLG Essential+™, demonstrating the power of the Company’s approach, unique expertise and differentiated precision fermentation platform.

Beta-lactoglobulin is a potent and highly nutritious dairy protein  

The predominant protein in bovine whey, beta-lactoglobulin (BLG) has attracted considerable food-producer interest for its high-quality nutrition and advantageous properties in food product formulation.

Its nutritional profile is impressive, boasting a larger amount of essential and branched-chain amino acids than whey. For example:

BLG contains 45% more leucine than commercially available whey protein isolates, which is particularly important for muscle synthesis.BLG is tasteless, stable across a wide pH range and can tolerate heat, making it the ideal ingredient for versatile product formulations, from clear protein drinks to alternative dairy or bakery products.

21st.BIO expects its customers’ own production of beta-lactoglobulin to be incorporated into the formulation of foods such as baked goods and alternative dairy products, as well as nutritional products for active or sports nutrition, weight management, and clinical and elderly nutrition.

Unique business model: One market approval for several dairy protein suppliers 

Companies engaged in 21st.BIO’s unique development program can now commercialize their own production of BLG Essential+™ in the U.S. market. Through 21st.BIO’s BLG program, customers gain access to the world’s most advanced production strains and precision fermentation processes – and optimizations over time. Furthermore, 21st.BIO is supporting customers in upscaling their production all the way to full-scale ingredient production. The Company’s diverse global customer base spans food-tech start-ups to large food ingredients manufacturers. BLG Essential+™ is the first food protein out of a portfolio of protein ingredients that 21st.BIO will take to the market via this model. 

21st.BIO gets solutions to market at an unprecedented pace 

With a strong track record and productive microorganisms licensed from Novonesis (formerly Novozymes), 21st.BIO is bringing solutions to market at an unprecedented pace, enabling customers to bypass years of development and market approval for direct entry into the U.S. market and empowering customers to produce any food, materials, agriculture, or biopharma-related protein or peptide of interest, and scale production to industrial levels to ensure large-scale availability and cost-effectiveness. Customers in 21st.BIO’s development programs benefit from continuous optimizations of strain and process for improved commercial attractiveness.

Comprehensive support every step of the way to get products to market 

“We bring our customers access to technology and skills they could not get anywhere else,” said 21st.BIO co-founder and CSO Per Falholt. 

And 21st.BIO co-founder and CEO Thomas G. Schmidt continues: “We’re not just a technology provider – we’re a partner to our customers’ on their product journey, ensuring their success from development to full-scale manufacturing. We make products, not projects. Our ambition is to empower our customers to focus more on application, business development, low-cost production and innovation. And this shows all the way through our business model, which is designed such that our success at 21st.BIO depends on our customers’ success in the market with a product; not just on project completion.” 

21st.BIO derisks product development and supports customers from strain development, fermentation processes, purification protocols, pilot production and upscaling guidance, to the regulatory approvals for market entry. 21st.BIO is working on additional proteins, including proteins for both foods, materials, agriculture and beyond.

NOTES TO EDITORS 

About 21st.BIO  

21st.BIO was founded with one simple mission: to make leading industrial scale precision fermentation technology accessible to as many as possible, so companies can successfully take biotech innovations to market at a competitive price. 21st.BIO’s founders saw that too often, great bio innovation and molecules fail to translate into commercial success. The innovation is ready, the market is there, but production costs remain too high for the product to go mainstream. Industry insiders call it the `valley of death’, and that’s exactly what 21st.BIO intends to bridge. 

Founded in 2020, 21st.BIO is headquartered in Copenhagen, Denmark, and has a world-class R&D team as well as laboratories in both Copenhagen, Denmark and Davis, California. On a mission to support bio industrial companies globally in upscaling from molecule innovation to large-scale production, 21st.BIO enables its customers to meet market demands, and thereby advance the green transition globally. 21st.BIO focuses on developing industrial production technology for proteins and other molecules of interest for food, materials, and agricultural industries. Established as a fully integrated end-to-end partner, 21st.BIO supports its customers from technical assessment, strain development and optimization, production processes and upscaling, tech transfer to large scale manufacturing and regulatory services.  

21st.BIO’s fermentation technology is in part licensed from Novonesis, who have developed and perfected their platform over several decades. Novonesis is a global leader in enzymes, functional proteins and microorganisms for high value products in food, household care, and agriculture.  

Press contact:
Mathilde Pinon
Marketing & Business Development Manager
m.pinon@21st.bio

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/21st-bio/r/21st-bio-obtains-self-affirmed-gras-status-for-its-precision-fermented-beta-lactoglobulin–21st-bio-,c4032851

The following files are available for download:

https://mb.cision.com/Main/22992/4032851/2980200.pdf

Press release (PDF)

https://news.cision.com/21st-bio/i/21st-bio-pilot-plant-facility,c3330348

21st BIO pilot plant facility

https://news.cision.com/21st-bio/i/21st-bio-strain-engineering,c3330346

21st BIO strain engineering

https://news.cision.com/21st-bio/i/21st-bio-fermentation,c3330347

21st BIO fermentation

https://news.cision.com/21st-bio/i/21st-bio-co-founders,c3330349

21st BIO co-founders

https://news.cision.com/21st-bio/i/per-falholt-co-founder-and-cso-21st-bio,c3330350

Per Falholt co-founder and CSO 21st BIO

https://news.cision.com/21st-bio/i/thomas-schmidt-co-founder-and-ceo-21st-bio,c3330351

Thomas Schmidt co-founder and CEO 21st BIO

https://news.cision.com/21st-bio/i/21st-bio-hq-in-copenhagen,c3330353

21st BIO HQ in Copenhagen

https://news.cision.com/21st-bio/i/21st-logo-dot-pink,c3330352

21st logo dot pink

 

View original content:https://www.prnewswire.co.uk/news-releases/21stbio-obtains-self-affirmed-gras-status-for-its-precision-fermented-beta-lactoglobulin-21stbio-customers-can-now-enter-the-us-market-with-their-own-production-using-21stbio-technology-302237720.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Capital Advantage, Inc. Offers Tailored Financial Services for Kaiser Permanente® and TPMG Employees

Published

on

By

WALNUT CREEK, Calif., Jan. 10, 2025 /PRNewswire/ — Capital Advantage, Inc., a trusted name in wealth management, is proud to highlight its specialized services designed to meet the unique financial needs of Kaiser Permanente® and The Permanente Medical Group (TPMG) employees.

At Capital Advantage, we understand the complexities of Kaiser Permanente® and TPMG benefit plans. Our team is dedicated to helping healthcare professionals navigate their robust and often intricate benefit options. With over 30 years of expertise and a deep understanding of Kaiser’s offerings, we craft personalized financial plans to help maximize the value of our clients’ benefits.

“We recognize the unique challenges and opportunities that healthcare professionals face in managing their financial lives,” says Ian Castille, CFP®, Principal and Senior Financial Advisor at Capital Advantage, Inc.

Donna Zinman, CRPC®, Principal and Senior Advisor, adds, “Our goal is to educate our clients about their attractive benefit options and help them make the most of these opportunities.”

Key services for Kaiser Permanente® and TPMG employees include customized portfolio strategies and personalized guidance on retirement savings plans, identification of ideal pension options and annual open-enrollment benefit selections, advice on traditional vs. Roth 401(k) options, advanced tax-saving strategies (such as mega-backdoor Roth contributions), and simplification of retirement planning by working directly with Kaiser/TPMG’s benefits department. These services are designed to provide Kaiser/TPMG employees with peace of mind, confidence, and financial empowerment as they navigate their retirement and benefits planning.

About Capital Advantage, Inc.

Capital Advantage is a trusted, independently owned wealth management firm with over 40 years of experience helping individuals and families to achieve their financial goals. As a 100% fee-only fiduciary, Capital Advantage strives to provide financial peace of mind to each and every client, delivering large institution expertise with the personalized care and attention of a boutique firm. Our experienced advisors work closely with pre-retirees and retirees, women navigating unique financial journeys, and Kaiser Permanente® and The Permanente Medical Group (TPMG) employees to create strategies that provide clarity, confidence, and long-term success.

For more information on Capital Advantage’s services visit: Kaiser/TPMG Employees – Capital Advantage, Inc. or call (925) 299-1500 to contact one of our advisors for a no-cost initial consultation.

Disclaimer: Capital Advantage, Inc. is not affiliated, associated, authorized, endorsed by, or in any way officially connected with Kaiser Permanente® or TPMG (The Permanente Medical Group)

Limitations: No amount of experience, recognition, or past success, nor the achievement of any professional designation, certification, degree, or license should be construed by a client or prospective client as a guarantee that he/she will experience a certain level of results if Capital Advantage is engaged, or continues to be engaged, to provide investment advisory services. Please see Important Disclosure.

View original content to download multimedia:https://www.prnewswire.com/news-releases/capital-advantage-inc-offers-tailored-financial-services-for-kaiser-permanente-and-tpmg-employees-302348316.html

SOURCE Capital Advantage, Inc.

Continue Reading

Technology

NASA Sets Coverage for Firefly First Commercial Robotic Moon Launch

Published

on

By

WASHINGTON, Jan. 10, 2025 /PRNewswire/ — Carrying NASA science and technology to the Moon as part of the agency’s CLPS (Commercial Lunar Payload Services) initiative and Artemis campaign, Firefly Aerospace’s Blue Ghost Mission 1 is targeting launch Wednesday, Jan. 15. The mission will lift off on a SpaceX’s Falcon 9 rocket from Launch Complex 39A at the agency’s Kennedy Space Center in Florida.

Live launch coverage will air on NASA+ with prelaunch events starting Monday, Jan. 13. Learn how to watch NASA content through a variety of platforms, including social media. Follow all events at:

https://www.nasa.gov/live/

After the launch, Firefly’s Blue Ghost lander will spend approximately 45 days in transit to the Moon before landing on the lunar surface in early March. The lander will carry 10 NASA science investigations to further our understanding of the Moon’s environment and help prepare for future human missions to the lunar surface, as part of the agency’s Moon to Mars exploration approach. 

Science investigations on this flight aim to test and demonstrate lunar subsurface drilling technology, regolith sample collection capabilities, global navigation satellite system abilities, radiation tolerant computing, and lunar dust mitigation methods. The data captured could benefit humans on Earth by providing insights into how space weather and other cosmic forces impact Earth. 

The deadline has passed for media accreditation for in-person coverage of this launch. The agency’s media accreditation policy is available online. More information about media accreditation is available by emailing: ksc-media-accreditat@mail.nasa.gov.

Full coverage of this mission is as follows (all times Eastern):

Monday, Jan. 13
2:30 p.m. – Lunar science media teleconference with the following participants:

Chris Culbert, CLPS program manager, NASA’s Johnson Space CenterMaria Banks, CLPS project scientist, NASA Johnson

Audio of the teleconference will stream live on the agency’s website:

https://www.nasa.gov/live/

Media may ask questions via phone only. For the dial-in number and passcode, please contact the Kennedy newsroom no later than 1:30 p.m. EST Jan. 13, at: ksc-newsroom@mail.nasa.gov.

Tuesday, Jan. 14
1 p.m. – Lunar delivery readiness media teleconference with the following participants:

Nicola Fox, associate administrator, Science Mission Directorate at NASA HeadquartersJason Kim, CEO, Firefly AerospaceJulianna Scheiman, director, NASA science missions, SpaceXMark Burger, launch weather officer, Cape Canaveral Space Force Station’s 45th Weather Squadron

Audio of the teleconference will stream live on the agency’s website:

https://www.nasa.gov/live/

Media may ask questions via phone only. For the dial-in number and passcode, please contact the Kennedy newsroom no later than 12 p.m. EST on Tuesday, Jan. 14, at: ksc-newsroom@mail.nasa.gov.

Wednesday, Jan. 15
12:30 a.m. – Launch coverage begins on NASA+ and the agency’s website.

1:11 a.m. – Launch

NASA Launch Coverage
Audio only of the media teleconferences and launch coverage will be carried on the NASA “V” circuits, which may be accessed by dialing 321-867-1220, -1240, or -7135. On launch day, the full mission broadcast can be heard on -1220 and -1240, while the countdown net only can be heard on -7135 beginning approximately one hour before the mission broadcast begins.

On launch day, a “tech feed” of the launch without NASA TV commentary will be carried on the NASA TV media channel.

NASA Website Launch Coverage
Launch day coverage of the mission will be available on the NASA website. Coverage will include live streaming and blog updates beginning no earlier than 12:30 a.m. EST Jan. 15, as the countdown milestones occur. On-demand streaming video and photos of the launch will be available shortly after liftoff. For questions about countdown coverage, contact the Kennedy newsroom at 321-867-2468. Follow countdown coverage on our launch blog for updates.

NASA Virtual Guests for Launch
Members of the public can register to attend this launch virtually. Registrants will receive mission updates and activities by email, including curated mission resources, schedule updates, and a virtual guest passport stamp following a successful launch. Print your passport and get ready to add your stamp!

Watch, Engage on Social Media
Let people know you’re following the mission on X, Facebook, and Instagram by using the hashtag #Artemis. You can also stay connected by following and tagging these accounts:

X: @NASA, @NASAKennedy, @NASAArtemis, @NASAMoon

Facebook: NASA, NASAKennedy, NASAArtemis

Instagram: @NASA, @NASAKennedy, @NASAArtemis

Coverage en Español
Did you know NASA has a Spanish section called NASA en español? Check out NASA en español on X, Instagram, Facebook, and YouTube for additional mission coverage.

Para obtener información sobre cobertura en español en el Centro Espacial Kennedy o si desea solicitar entrevistas en español, comuníquese con Antonia Jaramillo o Messod Bendayan a: antonia.jaramillobotero@nasa.gov o messod.c.bendayan@nasa.gov.

For media inquiries relating to the launch provider, please contact SpaceX’s communications department by emailing: media@spacex.com. For media inquiries relating to the CLPS provider, Firefly Aerospace, please contact Firefly’s communication department by emailing: press@fireflyspace.com.
For more information about the agency’s CLPS initiative, see:

https://www.nasa.gov/clps

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nasa-sets-coverage-for-firefly-first-commercial-robotic-moon-launch-302348344.html

SOURCE NASA

Continue Reading

Technology

Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials

Published

on

By

New findings support the company’s neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized depression treatment

PALO ALTO, Calif., Jan. 10, 2025 /PRNewswire/ — Universal Brain, a pioneering technology company focused on transforming mental healthcare through neuroscience, today announced the publication of its latest peer-reviewed study, “Neurotyping depression using multiple event-related potentials (ERPs): Leveraging task-based variation to predict remission in depression,” the paper introduces a novel framework for detecting unique neurophysiological patterns that can help predict which depressed patients are most likely to achieve remission from depression.

“By combining several EEG paradigms with novel statistical analyses, we’re moving closer to a future where depression therapies can be precisely tailored to each individual,” said Kazu Okuda, Chief Executive Officer of Universal Brain. “In particular, we are poised to leverage a battery of EEG paradigms to better subtype depression – which will pave the way for more precision in treatment development and selection.  These functional measures of brain activity (i.e., neurotypes) will be used to determine what treatment works best for whom.”

Key Highlights of the Study

Multi-Task ERP Analyses
The study leveraged multiple cognitive and emotional tasks to capture a broader spectrum of brain responses, thereby enabling more robust classification of distinct depression subtypes.Predictive Neurotyping
Through comprehensive ERP assessment, researchers identified patterns linked to a higher likelihood of remission in depression, paving the way for more targeted clinical strategies. Combining ERPs from multiple tasks outperformed classifications based on more traditional single-task analyses.Implications for Precision Psychiatry
These findings underscore the potential of individualized treatment pathways—an approach backed by emerging research in the field of precision psychiatry, which calls for data-driven, personalized solutions to improve outcomes in mental health.

“This work is especially exciting because it bridges the gap between laboratory-based assessments and potential real-world clinical practice. We believe our new method can help physicians potentially select treatment but also help clinicians fine-tune therapeutic interventions to an individual’s unique neural signature,” commented Greg Hajcak, Chief Scientific Advisor of Universal Brain. “By leveraging multiple ERPs in varying tasks, we can aim to better predict who will respond to specific treatments, a key step in transforming how we approach depression management.”

Championing Precision Psychiatry

Universal Brain’s overarching mission is to integrate cutting-edge neuroscience with clinical insights to advance precision psychiatry—a transformative model of care that personalizes interventions based on individual biological, behavioral, and environmental factors. This focus resonates with emerging trends in psychiatric research to enhance treatment outcomes.

In close collaboration with academic institutions, research hospitals, and clinical partners, Universal Brain continues to drive neuroscience-based innovation that bridges the gap between academic discoveries and real-world patient care.

For more information on Universal Brain’s research and the company’s commitment to developing neuroscience-driven solutions for mental health, please visit universal-brain.com or email us at media@universal-brain.com.

About Universal Brain

Universal Brain is a science-driven technology company dedicated to revolutionizing mental healthcare by unlocking the power of precision psychiatry. Drawing on advances in neuroscience, data analytics, and engineering, Universal Brain develops innovative tools and platforms that personalize psychiatric treatment and improve patient outcomes. To learn more, visit www.universal-brain.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/universal-brain-announces-publication-of-groundbreaking-depression-research-using-multiple-event-related-potentials-302348351.html

SOURCE Universal Brain

Continue Reading

Trending